Molecular modeling and UV–vis spectroscopic studies on the mechanism of action of reversed chloroquine (RCQ)  by Otelo, Vanessa A. et al.
Bioorganic & Medicinal Chemistry Letters 21 (2011) 250–254Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry Letters
journal homepage: www.elsevier .com/ locate/bmclMolecular modeling and UV–vis spectroscopic studies on the mechanism
of action of reversed chloroquine (RCQ)
Vanessa A. Otelo a, Antonio C. Sant’Ana b,, Dalva L. A. de Faria b, Carla M. S. Menezes a,,⇑
a Programa de Pós-graduação em Fármaco e Medicamentos, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, Av. Prof. Lineu Prestes,
580 Bl. 13 sup., 05508-000 São Paulo, SP, Brazil
bDepartamento de Química Fundamental, Instituto de Química, Universidade de São Paulo, Av. Prof. Lineu Prestes, 748 Bl. 4 inf., 05508-000 São Paulo, SP, Brazila r t i c l e i n f o
Article history:
Received 8 October 2010
Revised 1 November 2010
Accepted 2 November 2010
Available online 5 November 2010
Keywords:
Reversed chloroquine
Chloroquine
Heme
Antimalarial
Multiple ligand0960-894X  2010 Elsevier Ltd.
doi:10.1016/j.bmcl.2010.11.019
⇑ Corresponding author. Tel./fax: +55 21 25626478
E-mail addresses: vaotelo@yahoo.com.br (V.A. Ot
(A.C. Sant’Ana), dlafaria@iq.usp.br (D.L.A. de Faria), ca
casmenezes@yahoo.com (C.M.S. Menezes).
 Present address: Departamento de Química, Institu
sidade Federal de Juiz de Fora, Rua José Lourenço Kelme
MG, Brazil.
 Present address: Laboratório de Avaliação e Sínt
(LASSBio, http://www.farmacia.ufrj.br/lassbio/), Faculda
Federal do Rio de Janeiro, PO Box 68024, 21944-971 R
Open access under the Ea b s t r a c t
Reversed chloroquine (RCQ) is a multiple ligand compound active against chloroquine-sensitive and
resistant falciparum malaria. It is composed by a 4-aminoquinoline moiety (like that present in chloro-
quine (CQ)) joined to imipramine (IMP), a modulating agent that also showed intrinsic antiplasmodial
activity against Brazilian Plasmodium falciparum isolates resistant to CQ. Molecular modeling and ultra-
violet–visible spectroscopy (UV–vis) studies strongly suggest that the interaction between RCQ and heme
is predominant through the quinoline moiety in a mechanism of action similar to that observed for CQ.
 2010 Elsevier Ltd. Open access under the Elsevier OA license.The paradigm of a multiple ligand on drug discovery emerged in
the last decade to provide structural features to modulate multiple
biological targets simultaneously in the same molecule.1 The use of
this new approach in the discovery of antimalarial drugs started
with the so-called ‘reversed chloroquine’ (RCQ) (Fig. 1), a chloro-
quine-like compound2 and has increased with the appointments
of dihydropyrimidone3 and acridone derivatives,4 new analogs of
reversed chloroquine,5,6 and recently, modiﬁed 4-aminoquinolines
and quinoline–acridine hybrids compounds.7 These multiple
ligand compounds have been able to modulate in vitro and
in vivo chloroquine Plasmodium falciparum resistance and, at the
same time, be active against sensitive strains. RCQ, its analogs
and the acridone derivatives were supposed to show an antimalar-
ial mechanism of action similar to chloroquine (CQ) (Fig. 1).2–7 CQ
is hypothesized to bind with heme, that corresponds to the toxic
metabolic product resulting from the hemoglobin degradation by
plasmodio.8,9.
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lsevier OA license.RCQ consists of a chloroquine-like moiety linked to the modu-
lating agent imipramine (IMP) (Fig. 1) by both side-chains. It can
thus be classiﬁed as a fused designed multiple ligand.1 The quino-
line moiety present in RCQ resembles the new antiplasmodial
agent AQ-13 (Fig. 1), a structural analog of CQ in which the
side-chain has been simpliﬁed to a propyl group. This new 4-ami-
noquinoline compound has been considered as a candidate to anti-
malarial agent, with pharmacokinetic and toxicity properties
similar to its prototype.10 Imipramine and its desmethyl metabo-
lite desipramine, two antidepressant drugs of the iminodibenzyl
chemical class, were reported as in vitro promising modulating
agents of CQ resistance in 1988.11 Nevertheless, the clinical combi-
nation of desipramine and CQ was unsuccessful.12 In a previous
study using isolates of Brazilian P. falciparum resistant to CQ, we
veriﬁed that both imipramine and desipramine showed intrinsic
antiplasmodial activity in detriment to its modulating effect.13
These data were further related to structural similarities between
CQ and IMP,14 features which allow us to hypothesize that IMP
also interacts with heme.
Since RCQ is a chloroquine–imipramine hybrid molecule, its
interaction with heme was investigated to simulate its probable
mechanism of action. Molecular modeling and ultraviolet–visible
(UV–vis) spectroscopy studies were used to address this issue.
The diprotonated form of RCQ (RCQ.2H+), that of the R-diaste-
reomer of chloroquine (CQ.2H+), and the monoprotonated form
of imipramine (IMP.H+) were considered in the molecular model-
ing studies. The PM3 semiempirical method15 was employed. The
Figure 1. Chemical structures of reversed chloroquine (RCQ), chloroquine (CQ), the antimalarial candidate AQ-13, and imipramine (IMP).
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right ring of the tricyclic moiety as the highest electronic density
regions for CQ.2H+ and IMP.H+, respectively. The HOMO (Highest
Occupied Molecular Orbital) distribution is also located on these
electron-rich heterocyclic regions. The LUMO (Lowest Unoccupied
Molecular Orbital) orbitals are concentrated around the charged
nitrogen atom of the IMP.H+ side-chain, whereas, for CQ.2H+, they
are located on the protonated quinoline ring. As a result of being a
hybrid molecule, RCQ.2H+ shows its highest electron density re-
gion and HOMO orbitals (Fig. 2B) located on the iminodibenzyl
moiety while LUMO orbitals (Fig. 2C) are distributed on the proton-
ated quinoline ring. These electronic features suggest that both
moieties of RCQ may interact with the heme group since, in the
case of CQ, such interaction is believed to occur through a co-facial
p–p complex, as further discussed. Moreover, the HOMO and
LUMO orbital distribution indicates the occurrence of a possible
intramolecular interaction between the quinoline and iminodiben-
zyl moieties of RCQ.
Since CQ is reported to bind cofacially to unligated faces of heme
(Fe(PPIX)) viap–p interaction, hematin (Fe(PPIX-OH)), one interme-
diate species in the heme detoxiﬁcation process, was chosen toFigure 2. Minimum energy conformers of RCQ.2H+ in the aqueous medium calculated u
orbital distributions at 0.032 eV. Atoms color: carbon (gray), nitrogen (blue), chlorine (gperform the docking study.16 Analysis of the best ﬁt, generated from
Goldscore, indicate that RCQ.2H+, CQ.2H+, and IMP.H complex by a
non-covalent mode with hematin (Fig. 3 illustrates the three com-
plexes formedwith the carboxylate specie of hematin). Chloroquine
(CQ.2H+) is planar to the iron–porphyrin system, with the quinoline
moiety orientated toward the planar and electron-rich periphery
region of hematin. In addition, the nitrogen aniline atom is
orientated toward the iron atom, establishing an electron transfer
interaction, while the side-chain interacts by attractive van der
Waals forces with the porphyrin system. No salt bridge (dipole–
dipole) interaction was observed between the protonated aliphatic
nitrogen atom and the carboxylic groups, in spite of the neutral or
carboxylate form of hematin. Thesemolecular interactions corrobo-
rate previous theoretical and experimental reports. The formation of
co-facial p–p complex between CQ.2H+ and hematin was ﬁrst
reported by Fitch et al.17 and have been supported by different
experimental techniques such as nuclear magnetic resonance,18
Mössbauer,19 photoacoustic spectroscopy,20 UV–vis spectropho-
tometry,21,22 resonance Raman,16 and theoretical methods.23,24
Imipramine (IMP.H+) complexes similar to chloroquine
(CQ.2H+). The right benzene ring of the iminodibenzyl moiety issing PM3 semiempirical method: (A) in the tube model; (B) HOMO and (C) LUMO
reen), and hydrogen (white).
Figure 3. Structures of the complexes formed between hematin (carboxylate
specie, C = white, N = blue, O = red, Fe = magenta, and H = cyan) and RCQ.2H+
(yellow), CQ.2H+ (red) and IMP.H+ (green). The ligands are superimposed. Only
polar hydrogen atoms are displayed.
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p–p stacking interaction. In addition, van der Waals forces are
present between the remaining heterocyclic moiety and the side-
chain, which superimposes that of CQ.2H+ (Fig. 3). Once more, no
salt bridge interaction is observed between the protonated nitro-
gen atom (IMP.H+) and the carboxylic oxygen atoms of hematin.
Reversed chloroquine (RCQ.2H+) docks preferentially by its quino-
line moiety with the iron–porphyrin part of hematin. A coplanar
orientation is observed between the quinoline moiety and hema-
tin; furthermore, the RCQ.2H+ quinoline moiety superimposes
both the quinoline ring of CQ.2H+ and the right ring of the imino-
dibenzyl moiety of IMP.H+. Nevertheless, the quinoline orientation
is slight different from that of chloroquine since the RCQ larger
side-chain and the iminodibenzyl moiety also interact by van der
Waals forces and orthogonal p-stacking with the periphery border
of hematin. These results also suggest that steric properties could
inhibit the approximation and binding of the quinoline moiety to
hematin, explaining the observed loss of activity to some chloro-
quine reversed analogs.5 Moreover, it is important to note that
similar results were obtained when the hematin l-oxo dimmer
(Fe(III)PPIX l-oxo dimer) was employed.
The UV–vis spectroscopy study considered a 1 hematin:2 com-
pound stoichiometric ratio.21,22 The spectra were obtained from
aqueous solutions, prepared at pH 7.4 and 5.5 (resembling the food
vacuole of plasmodio),25of the isolated compounds (CQ, IMP, and
hematin), from binary mixtures (CQ + IMP; CQ + hematin, and
IMP + hematin) and from the ternary mixture (CQ + IMP + hema-
tin). In the later, hematin solution was added to a previously pre-
pared solution containing CQ and IMP. For each mixture, to
emphasize the chemical interaction effect, the UV–vis spectrum
was compared to the spectrum generated mathematically by add-
ing up the spectra from the isolated species.
The main advantages of using UV–vis spectroscopy in the study
of molecular chemical interactions are that it allows the use of di-
luted solutions, compatible with biological or biochemical systems,
and that such interactions affect the molecular energy levels caus-
ing shifts in band positions (bathochromic or hypsochromic shift),
band broadening and/or changes in intensity (hyperchromism and
hypochromism). With our previous knowledge of the electronic
transitions responsible for the absorption bands, these changes
can be used to track the nature of the chemical interaction and also
its magnitude. Electrostatic interactions are much more difﬁcult to
detect since the effect on the energy levels is frequently negligibleexcept when it affects molecular structure. Heme group presents
two p–p* transitions corresponding to Soret or B bands around
380 nm and Q bands at near 550 nm. The Soret bands are assigned
to the transition to the second excited state (S0?S2) while Q bands
populate the ﬁrst excited state (S0?S1),26 with the transition mo-
ments strongly coupled through conﬁguration interaction. In par-
ticular, Soret bands are sensitive to the chemical environment,
and thus can be used to investigate interactions involving the
heme group, including dimerization. It was recently shown that
Soret has two bands: one at 385 nm, sensitive to the balance
monomer–dimer, and another at 345 nm that independs of the
interaction of the monomer–dimer.27 The literature reports that
dimerization causes a decrease in the 385 nm absorption band
and the dimer is the predominant species in acidic solution.28 In
this study the Soret bands were used to analyze the interactions
of the formed complexes.
Figure 4A and B shows the UV–vis spectra of aqueous buffer
solutions, at pH 7.4 and 5.5, containing CQ or IMP, or both mixed,
besides the sum of the spectrum of each isolated compound. Com-
paring the spectra of CQ and IMP isolated compounds at both pHs,
it is clear that there is no signiﬁcant effect of the pH on their spec-
tra, an expected behavior since no additional protonation is ex-
pected at pH 5.5 due to the respective pKa values (CQ pKa1 = 10.8,
pKa2 = 8.4 and IMP pKa = 10.2).29 Other events, such as dimeriza-
tion, are not reported for these compounds at the employed pH
range. Hypochromism in the 200–250 nm absorption region is
the only effect in the spectrum of the binary mixture that can be
observed when compared with the sum of the spectra of each iso-
lated compound. In this region, both compounds present p–p*
transitions and the detected hypochromism may suggest that CQ
and IMP interact through their heterocyclic moieties, reinforcing
molecular modeling results. With the data available so far, it is
not possible to conclude whether pH has or does not have an inﬂu-
ence on the interaction, since the apparent less pronounced hypo-
chromic effect at pH 5.5 may be an artifact due to the proximity of
the spectral window edge.
From the heme aqueous solution (Fig. 5), the well known pH
dependent monomer–dimer equilibrium27 is responsible for the
change in the Soret band shape when the two pHs are considered.
As discussed above, dimerization causes a decrease in the intensity
of the 385 nm Soret band28 that makes clear that the dimer is the
predominant species in acid solutions (Fig. 5C/D), while the
monomer is the predominant species at pH 7.4 (Fig. 5A/B). The
interaction of both compounds with heme is the main target of
this UV–vis investigation. Binary and ternary mixtures were
prepared and their spectra were compared with the sum of the
isolated compounds spectra. Such a procedure highlights the even-
tual effect of a chemical interaction. A similar behavior, albeit less
pronounced, is observed in the UV–vis spectra of the IMP-heme
system (hypochromism of Soret bands and no signiﬁcant changes
in the band shapes, particularly in the case of heme) (Fig. 5B and
D), again suggesting the existence of a weak interaction involving
the IMP and heme aromatic rings. Concerning CQ, its interaction
with heme was already investigated by UV–vis spectroscopy21,22
and our results are in agreement with such works (Fig. 5A and
C). The most remarkable feature in the CQ/heme spectrum is the
change in the Soret band shape at both pHs, indicating that the
compound is interfering with the heme monomer–dimer equilib-
rium. This reinforces the molecular modeling results, which indi-
cated a relatively strong interaction via p-stacking. As expected,
due to the simultaneous equilibrium present, the contribution of
heme dimeric form to the spectrum of the CQ–heme mixture is
more pronounced at pH 5.5, as shown by the strong absorption
at 385 nm. From the UV–vis data reported here, it is clear that
the IMP/heme interaction is much weaker than the CQ/heme
one.
Figure 4. UV–vis spectra at pH 7.4 (A) and 5.5 (B) aqueous buffer solutions of chloroquine (CQ), imipramine (IMP), and a mixture of both solutions (CQ/IMP) and the result of
adding up the spectrum of each isolated compound (CQ + IMP).
Figure 5. UV–vis spectra at pH 7.4 (A and B) and 5.5 (C and D) aqueous buffer solutions of CQ, IMP, heme, and the binary mixtures CQ/heme (A and C) and IMP/heme (B and
D). The sum of CQ and heme spectra (CQ + heme) and of IMP and heme spectra (IMP + heme) was also included for comparison purposes.
V. A. Otelo et al. / Bioorg. Med. Chem. Lett. 21 (2011) 250–254 253The UV–vis spectra of the ternary mixtures (CQ/IMP/heme), at
both pHs (Fig. 6A and B) show band positions and relative intensi-
ties similar to those obtained by the sum of the spectra of thebinary CQ/heme and the isolated IMP solutions (CQ/heme + IMP),
irrespective of the pH, but different from any other combination
sum of the spectra of isolated + binary solutions. This fact
Figure 6. UV–vis spectra at pH 7.4 (A) and 5.5 (B) aqueous buffer solution of ternary mixture CQ/IMP/heme and the sums of the spectra of binary mixtures from CQ, IMP, and
heme with the spectrum of the remaining isolated compound (CQ/IMP + heme, CQ/heme + IMP and IMP/heme + CQ), and the sum of the spectra of each isolated compound
(CQ + IMP + heme), all original spectra obtained in aqueous buffer solution.
254 V. A. Otelo et al. / Bioorg. Med. Chem. Lett. 21 (2011) 250–254reinforces previous evidences that the CQ/heme interaction is
stronger than the IMP/heme one, indicating that CQ is the pre-
ferred heme target. A similar interaction may occur with RCQ.
In conclusion, stereoelectronic features and docking complexes
of CQ, IMP and RCQ combined with a careful UV–vis spectroscopy
study indicated heme as the molecular target of action of RCQ, as
previously supposed2–7 and veriﬁed to occur biochemically,6 by
quinoline moiety interaction.
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